← Leaderboards
Parjit Kaur
Georgia State University
$1,825,787
Attributed
$2,768,574
Total exposure
2
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $399.9K · FY2005–18$500K$375K$250K$125K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
Funding mix
By agency
NIH$2,768,574 · 2
By mechanism
R01$2,768,574 · 2
Top collaborators
- Margo A Brinton6 shared
Others in their field
Top investigators on “Endoplasmic Reticulum”
- Randal J. Kaufman · Indiana University Indianapolis$33,249,957
- Ralph Parchment · Leidos Biomedical Research, Inc.$25,266,647
- Peter Arvan · University Of Michigan At Ann Arbor$23,625,830
- Feroz R Papa · University Of California San Francisco$18,595,073
- Zihai Li · Ohio State University$17,028,405
- J. Kevin Kevin Foskett · University Of Pennsylvania$16,942,170
Research focus
Endoplasmic ReticulumExtracellularDengue VirusC-TerminalDoseEndocytosisAffectAntiviral Therapy2-5a SynthetaseBacteriaAllelesDisease ResistanceAnimalsDouble-Stranded RnaBrainAntiviral AgentsC57bl/6 MouseCell Culture TechniquesCellsAutosomal Dominant TraitCleaved CellComplexCongenicFamily
Grant awards (10)
Functional analysis of flavivirus genetic resistance$399,885
R01 · FY2018 · AI
Functional analysis of flavivirus genetic resistance$399,885
R01 · FY2017 · AI
Functional analysis of flavivirus genetic resistance$350,599
R01 · FY2016 · AI
Functional analysis of flavivirus genetic resistance$35,594
R01 · FY2016 · AI
Functional analysis of flavivirus genetic resistance$346,899
R01 · FY2015 · AI
Functional analysis of flavivirus genetic resistance$352,712
R01 · FY2014 · AI
DOXORUBICIN TRANSPORT ATPase: MODEL FOR DRUG RESISTANCE$214,500
R01 · FY2005 · GM
DOXORUBICIN TRANSPORT ATPase: MODEL FOR DRUG RESISTANCE$214,500
R01 · FY2004 · GM
DOXORUBICIN TRANSPORT ATPase: MODEL FOR DRUG RESISTANCE$214,500
R01 · FY2003 · GM
DOXORUBICIN TRANSPORT ATPase: MODEL FOR DRUG RESISTANCE$239,500
R01 · FY2002 · GM